(Q37869437)

24 August 2017

1 reference

title

Targeted therapy in pediatric and adolescent oncology (English)

1 reference

24 August 2017

1 reference

Mark L Bernstein

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

117

1 reference

24 August 2017

issue

10 Suppl

1 reference

24 August 2017

page(s)

2268-2274

1 reference

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Advances in the biology and therapy of patients with chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Advances in the treatment of gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Alveolar soft-part sarcoma: a review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Response to sunitinib malate in advanced alveolar soft part sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

7 January 2021

Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

7 January 2021

Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

7 January 2021

Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26050

7 January 2021

Identifiers

DOI

10.1002/CNCR.26050

1 reference

24 August 2017

1 reference